Avalo Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company specializing in immune dysregulation treatments, has announced its participation in two upcoming investor conferences. Management will conduct a fireside chat at the HCW Annual Inflammation & Immunology Virtual Conference on June 30, 2025, at 11:00 am ET. Additionally, they will participate in 1x1 meetings at the BTIG Virtual Biotechnology Conference 2025, scheduled for July 29-30, 2025. Webcasts and replays will be available on the company's investor relations website for at least 30 days after the events.

News Market Reaction – AVTX

+3.23%

+3.23% Session move

In the trading session that priced this news, AVTX gained 3.23%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences:

HCW Annual Inflammation & Immunology Virtual Conference
Fireside Chat
June 30, 2025, at 11:00 am ET

BTIG Virtual Biotechnology Conference 2025
1x1s
July 29-30, 2025

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. For more information about Avalo, please visit www.avalotx.com.

About AVTX-009 

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com

FAQ

When is Avalo Therapeutics (AVTX) presenting at the HCW Annual Inflammation Conference 2025?

Avalo Therapeutics will present a fireside chat at the HCW Annual Inflammation & Immunology Virtual Conference on June 30, 2025, at 11:00 am ET.

What investor conferences is AVTX attending in summer 2025?

AVTX is participating in two conferences: the HCW Annual Inflammation & Immunology Virtual Conference on June 30 and the BTIG Virtual Biotechnology Conference on July 29-30, 2025.

Where can I watch Avalo Therapeutics' (AVTX) conference presentations?

The webcasts and replays will be available in the News/Events section of Avalo Therapeutics' investor relations website at https://ir.avalotx.com for at least 30 days.

What is Avalo Therapeutics' main focus as a company?

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation.